Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.
The in vitro activity of sparfloxacin (CI-978; AT-4140) was compared with those of other antimicrobial agents against isolates of staphylococci, enterococci, and various respiratory tract pathogens. Sparfloxacin was the most active drug tested against staphylococci (MIC for 90% of the strains tested [MIC90], 0.125 micrograms/ml) and enterococci (MIC90, 1.0 microgram/ml). It was also active against Haemophilus influenzae (MIC90, less than or equal to 0.06 microgram/ml), Moraxella (Branhamella) catarrhalis (MIC90, 0.125 microgram/ml), Streptococcus pneumoniae (MIC90, 0.5 microgram/ml), and Streptococcus pyogenes (MIC90, 1.0 microgram/ml).
Simor
A E
AE
Department of Microbiology, Mount Sinai Hospital, University of Toronto, Ontario, Canada.
Fuller
S A
SA
Low
D E
DE
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013210:Staphylococcus / Q000187:drug effects*; D013291:Streptococcus / Q000187:drug effects*
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C061363:sparfloxacin